Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aclaris Therapts (ACRS)

Aclaris Therapts (ACRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aclaris Therapts 701 LEE ROAD SUITE 103 WAYNE PA 19087 USA

www.aclaristx.com P: 484-324-7933 F: 484-320-2344

Description:

Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.

Key Statistics

Overview:

Market Capitalization, $K 84,401
Enterprise Value, $K 44,521
Shares Outstanding, K 70,925
Annual Sales, $ 31,250 K
Annual Net Income, $ -88,480 K
Last Quarter Sales, $ 17,570 K
Last Quarter Net Income, $ -1,490 K
EBIT, $ -90,740 K
EBITDA, $ -89,880 K
60-Month Beta 0.22
% of Insider Shareholders 5.50%
% of Institutional Shareholders 98.34%
Float, K 67,024
% Float 94.50%
Short Volume Ratio 0.59

Growth:

1-Year Return -86.50%
3-Year Return -95.01%
5-Year Return -81.23%
5-Year Revenue Growth 209.71%
5-Year Earnings Growth 61.54%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.30 on 02/27/24
Latest Earnings Date 05/13/24
Earnings Per Share ttm -1.55
EPS Growth vs. Prev Qtr 26.83%
EPS Growth vs. Prev Year 26.83%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ACRS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -64.56%
Return-on-Assets % -49.10%
Profit Margin % -283.14%
Debt/Equity 0.00
Price/Sales 2.66
Price/Cash Flow N/A
Price/Book 0.55
Book Value/Share 2.22
Interest Coverage -15.13
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar